Nearly a third of English NHS trusts using Palantir's health data platform are performing fewer patient procedures than before the system went live.
The findings raise questions about the efficacy of the software and the value of the government's investment in the technology. If a data platform intended to streamline operations is associated with a decline in patient throughput, it may signal implementation failures or flawed performance claims.
The analysis was conducted by the campaign group Foxglove, which utilized data obtained through Freedom of Information requests [1]. According to the group's findings, approximately 30% [1] of the trusts utilizing the Foundry Data Platform (FDP) have seen a decrease in the number of procedures carried out since the platform's adoption [1].
Palantir's contract with the NHS is valued at £330 million [3]. The platform was designed to integrate disparate data sources to improve operational efficiency across hospitals in England [1], [2]. However, the Foxglove data suggests that the results of this rollout have been uneven across different trusts [1].
The discrepancy between the promised efficiency gains and the observed data has prompted calls for increased scrutiny of the contract [1]. Critics said that the high cost of the software should be matched by clear, measurable improvements in patient care, and hospital capacity [2].
NHS trusts in England have been integrating the FDP to manage patient flows and resource allocation [2]. While some trusts may be seeing benefits, the fact that a significant portion are performing fewer procedures suggests the technology's impact varies by location or management style [1].
“Nearly a third of English NHS trusts using Palantir's health data platform are performing fewer patient procedures.”
This development highlights the tension between the procurement of high-cost 'big data' solutions and the actual delivery of frontline healthcare services. If the FDP cannot consistently demonstrate an increase in patient throughput, the NHS may face political pressure to justify the £330 million expenditure or renegotiate the terms of the partnership based on performance metrics.
